Next Pharma Inc. (NPI) is a biotechnology company focusing on developing and commercializing products for the early detection, diagnosis, treatment and monitoring the recurrence of cancer in addition to treat bacterial, fungal and viral infections including HCV infection. Next Pharma’s novel products are: a blood test that can measure the blood level of Aspartyl (Asparaginyl) β-Hydroxylase (AABH) and two Peptide Based Drug candidates (cLF-671 and cLF-672) that should treat HCV and different types of Cancer. AABH (a novel cancer bio-marker), cLF-671 and cLF-672 (two novel Therapeutic engineered peptides) are the products which make the foundation of our breakthrough technology. Next Pharma, is closing its Series C financing for a total of $14 million (Lead Director Kiarash Moshiri) and will be in a strong position to complete the animal study of its lead anti-Cancer and anti-HCV Peptide Based Drugs, as well as pursuing its late-stage pre-clinical candidates toward integrated cancer management. Next Pharma’s lead Peptide Based Anti-Cancer and Anti-HCVDrug candidates, and it’s late-stage pipeline of pre-clinical candidates, as well as it’s cancer diagnostic products, constitute Next Pharma’s integrated cancer management program. Relaying on our hard working in-house senior scientists and our worlds class collaborators, we strongly believe that we will pursue this extraordinary program. Beyond our lead Peptide Based Drug candidates and AABH based Early diagnostic cancer tests, our early-stage next pipeline of products consists of Radio-immuno-imaging to determine the site and size of tumor. I this pipeline of products, we would use a radioisotope-labeled, all human, anti-AABH antibody and radio-immunotherapy using high-energy, short-lived alpha or beta emitting radioisotopes bound to the anti-AABH antibody to specifically target cancer cells.
